CullmanTimes.com - Cullman, Alabama

Health

July 12, 2013

Fish-oil pills lure drugmakers though benefits remain unproven

Fish oil has been touted as useful for everything from growing hair to treating clinical depression. Now drug makers are stepping up their promotion of its benefits for treating heart disease.

AstraZeneca, Amarin and GlaxoSmithKline are betting the market for prescription fish-oil pills will follow the success of cholesterol-lowering drugs including Lipitor, once the world's best-selling medicine with revenue of $13 billion a year.

Heart disease remains the world's biggest killer, accounting for 30 percent of global deaths, even as statins and other treatments have become more widely used. Now that Lipitor and many other statins have cheaper, generic competitors, drugmakers are looking for new ways to tackle the array of conditions that can lead to heart disease, including coupling triglyceride treatments with existing cholesterol-lowering pills for a one-two punch.

 "The number of people with elevated triglyceride levels is rising rapidly across the world, due in part to the increasing prevalence of obesity and diabetes," AstraZeneca Chief Executive Officer Pascal Soriot said when he bought fish-oil pill maker Omthera Pharmaceuticals Inc. for $443 million last month. "There is a clear need for effective and convenient alternatives to some of the existing treatments."

Unlike capsules that can be bought in health-food stores, the drugmakers' products are available only with a prescription, are highly concentrated and undergo a several-step purification process approved by the U.S. Food and Drug Administration.

There's a hitch, however. Statins have been proven in studies to cut heart risk. The benefits of fish-oil pills are less certain. Though they target triglycerides, fatty substances in the blood that have been linked to a higher risk of heart attacks, little evidence exists that the pills prevent heart attacks.

"It's very unclear what role fatty acids play for cardiac patients," Mark Urman, a member of the American College of Cardiology Prevention Committee and practicing cardiologist at Cedars-Sinai Heart Institute, said in an interview. "The lab tests look better, but has it done the patient any good?"

Study results have been mixed. Japanese research on almost 19,000 people who took fish oil with a statin had a 19 percent lower risk of heart attacks, sudden cardiac death and other major coronary events, compared with those who took a statin alone.

A late-stage trial of Vascepa sponsored by Amarin found that it cut triglyceride levels by almost 22 percent at a 4-gram dose and 10 percent at a 2-gram dose without raising cholesterol levels in patients taking statins.

Other trials have shown little or no benefit. A study of more than 12,500 patients showed that a 1-gram daily dose of omega-3 fatty acids didn't prevent death or other cardiovascular events compared with placebo, according to an article in the New England Journal of Medicine in June 2012. And a review of data from 68,000 patients who took fish oil supplements over 24 years showed no reduction in risk of heart attack, stroke and death, the Journal of the American Medical Association said in September.

If cleared by regulators, AstraZeneca's Epanova would be the latest prescription pill to enter the market. It would bolster the London-based company's best-selling drug, a statin called Crestor, once it faces generic competition in 2016. While the drugmaker is still formulating its strategy, the Crestor sales team will pitch the product as an added benefit to the statin, said William Mongan, AstraZeneca's executive director of U.S. business development.

Amarin won U.S. approval to market Vascepa to people who have triglyceride levels of 500 milligrams per deciliter of blood or greater, a group of about 4 million people, according to the Dublin-based drugmaker. It's also seeking clearance to sell Vascepa for an additional 40 million people who have triglyceride levels between 200 milligrams and 500 milligrams, a "multi-billion dollar market opportunity."

Glaxo, whose Lovaza has brought in almost 2.5 billion pounds ($3.8 billion) in sales in the past five years, is more guarded about the market's prospects. In its 2012 annual report, the London-based drugmaker said the market had declined by 7 percent compared with 2011. Economic pressures have resulted in fewer doctor visits and reduced testing for conditions such as very high triglycerides that don't have any obvious symptoms, Glaxo said.

Without much evidence to support the claim that the pills cut heart risk, health-care purchasers remain skeptical of the benefits. Britain's medical spending watchdog, the National Institute for Health and Care Excellence, this month said it no longer recommends that heart attack survivors take fish-oil pills to prevent further heart attacks, citing their "minimal" benefit.

"It should be clear that they are not alternatives to statins," Cedars-Sinai's Urman said. He prescribes them predominately for patients who are in danger of developing pancreatitis, a painful inflammation of the pancreas caused by elevated triglyceride levels.

Vascepa has a long way to go to catch Lovaza. The drug had $4.3 million in sales between January and the end of April compared with $424.6 million for Lovaza, according to Symphony Health, a U.S. consulting firm. Amarin had to hire its own sales force after failing to find either a buyer for the company or a partner to help market Vascepa.

Amarin has fallen 60 percent in the last year and closed yesterday at $5.68, giving the drugmaker a market value of $854 million.

Analysts predict Lovaza sales will decline about 1.4 percent this year, according to the average of eight estimates compiled by Bloomberg.

"Do we need more preparations on the market? No," said Robert Eckel, director of the lipid clinic at the University of Colorado Hospital at the Anschutz Medical Campus in Aurora, Colo., and past president of the American Heart Association. "Do we have all of the answers about whether they are beneficial or not? No, we don't have those yet."

 

1
Text Only
Health
  • COMMENTARY: An alternative diagnosis to ADHD: Schoolchildren need more time to move

    The Centers for Disease Control and Prevention tells us that in recent years, there has been a jump in the percentage of young people diagnosed with attention deficit and hyperactivity disorder, commonly known as ADHD: 7.8 percent in 2003 to 9.5 percent in 2007 to 11 percent in 2011.

    July 18, 2014

  • Guideline: Most healthy women can skip pelvic exam

    No more dreaded pelvic exam? New guidelines say most healthy women can skip the yearly ritual.

    July 1, 2014

  • Sanofi targets fake Viagra market with non-prescription Cialis

    Sanofi sees an attractive opportunity in the rampant market for counterfeit Viagra: luring men away from dodgy online pharmacies with an over-the-counter version of a competing erection drug.

    June 5, 2014

  • Hospital charges to treat chest pain jump 10 percent in a year

    The charge to treat Medicare patients with chest pain at U.S. hospitals rose 10 percent to $18,568 in just a year, the biggest rise seen among the most common inpatient procedures, according to federal data.

    June 2, 2014

  • Study: Both men and women feel less stress at work than at home

    In a newly released study in the Journal of Science and Medicine, researchers carefully examined the levels of the stress hormone, cortisol, of a variety of workers throughout the day. The data clearly showed that both men and women are significantly less stressed out at work than they are at home.
     And the women they studied said they were happier at work. While the men said they felt happier at home.

    May 26, 2014

  • Jobless contend with weight gain as they search for work

    A subject long ignored by policymakers, and one that unemployment counselors are too sheepish to raise with job seekers, the link between bulging waistlines and joblessness is now of intense interest to researchers studying the long-term effects of the country's economic malaise.

    May 12, 2014

  • COMMENTARY: Helmets won't protect your kids from concussions

    When I was a kid, helmets were for motorcyclists. Now I see children wearing helmets when they're scooting down sidewalks, skating, skiing, sledding and playing soccer. Last week one of my friends saw a helmeted kid power-walking in Prospect Park. You can even buy $40 baby helmets on Amazon, because, according to the product description, "babies will always fall taking their first steps."

    May 2, 2014

  • 400px-Cannabis_Plant.jpg How bad is marijuana for your health?

    The Journal of Neuroscience recently published a study linking recreational marijuana use to subtle changes in brain structure. The researchers, led by Jodi Gilman of Massachusetts General Hospital, identified increased gray matter density in the left nucleus accumbens and some bordering areas.

    May 1, 2014 1 Photo

  • American sunscreens need an upgrade

    The last time a new sunscreen ingredient came on the U.S. market, the Y2K bug was threatening to destroy our way of life. Intel had just introduced the Pentium III processor, featuring an amazing 500 MHz of computing power.

    April 24, 2014

  • Cuba is running out of condoms

    The newest item on Cuba's list of dwindling commodities is condoms, which are now reportedly in short supply. In response, the Cuban government has approved the sale of expired condoms.

    April 23, 2014